Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)

William Wierda, Thomas Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trneny, Martin J.S. Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Randy Davis, Nedjad Losic, Joris Wilms, Charlotte Russell, Anders Österborg

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number2
DOIs
StatePublished - Apr 2010

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this